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The hepatic stellate cell (HSC) is the primary cell responsible for the dramatic increase in the synthesis of
type I collagen in the cirrhotic liver. Quiescent HSCs contain a low level of collagen a1(I) mRNA, while
activated HSCs contain about 60- to 70-fold more of this mRNA. The transcription rate of the collagen a1(I)
gene is only two fold higher in activated HSCs than in quiescent HSCs. In assays using actinomycin D or
5,6-dichlorobenzimidazole riboside collagen a1(I) mRNA has estimated half-lives of 1.5 h in quiescent HSCs
and 24 h in activated HSCs. Thus, this 16-fold change in mRNA stability is primarily responsible for the
increase in collagen a1(I) mRNA steady-state level in activated HSCs. We have identified a novel RNA-protein
interaction targeted to the C-rich sequence in the collagen a1(I) mRNA 3* untranslated region (UTR). This
sequence is localized 24 nucleotides 3* to the stop codon. In transient transfection experiments, mutation of
this sequence diminished accumulation of an mRNA transcribed from a collagen a1(I) minigene and in stable
transfections decreased the half-life of collagen a1(I) minigene mRNA. Binding to the collagen a1(I) 3* UTR
is present in cytoplasmic extracts of activated but not quiescent HSCs. It contains as a subunit aCP, which is
also found in the complex involved in stabilization of a-globin mRNA. The auxiliary factors necessary to
promote binding of aCP to the collagen 3* UTR are distinct from the factors necessary for binding to the
a-globin sequence. Since aCP is expressed in both quiescent and activated HSCs, these auxiliary factors are
responsible for the differentially expressed RNA-protein interaction at the collagen a1(I) mRNA 3* UTR.
Cirrhosis is a major medical problem characterized by the
excessive production of extracellular matrix proteins in the
liver, including type I collagen (36, 41, 42). Hepatic stellate
cells (HSCs; also called Ito cells, lipocytes, or fat-storing cells)
are the major cell type responsible for collagen synthesis in the
cirrhotic liver (17, 63). In normal liver, quiescent HSCs store
vitamin A (24) and probably regulate hemodynamics (27, 55)
but express only trace amounts of type I collagen. Upon a
fibrogenic stimulus, HSCs become activated, a process in which
they lose vitamin A granules, proliferate, change morphologi-
cally into myofibroblasts, and increase their synthesis of extra-
cellular matrix proteins (15, 38). The development of methods
for the isolation and culture of HSCs has enabled in vitro
studies of these cells (12, 16). Culturing quiescent HSCs on
plastic causes activation similar to that seen in liver fibrosis in
vivo, including the large accumulation of collagen a1(I)
mRNA (16, 19, 28). This provides a simple model system with
which to study HSC activation and collagen gene regulation.
The transcriptional regulation of the type I collagen gene
a1(I) has been extensively studied (2, 5, 7, 53, 60). In trans-
genic mice, the human collagen a1(I) gene containing 2 kb of
the 59 flanking and 10 kb of the 39 flanking sequences is ex-
pressed in a proper tissue-specific manner and is responsive to
fibrogenic stimulus (8, 68). Promoter analysis of the collagen a
(I) gene has identified four sites of protein binding as revealed
by DNase I footprinting in vitro (51). Two of these binding
sites are for the ubiquitous transcription factors Sp1 and NF1,
bindings of which are mutually exclusive (45, 46). A transcrip-
tional enhancer has been reported in the first intron of the
a1(I) gene (6, 57); however, studies using transgenic mouse
have questioned the biological relevance of this observation
(59, 62). Protein factors interacting with the collagen a1(I)
gene have also been studied in quiescent and activated HSCs.
Footprinting analysis has shown a different pattern of DNase
I-resistant sites in the promoter, and DNA binding activity of
the Sp1 transcription factor is about twofold higher in activated
HSCs than in quiescent cells (52). These results are consistent
with a higher transcription rate of the collagen a1(I) gene in
activated than in quiescent HSCs. Transforming growth factor
b, a cytokine implicated in liver fibrogenesis (10, 32, 44), in-
creases collagen a1(I) mRNA steady-state levels severalfold
(26, 49, 65) in fibroblasts and activated HSCs. An increased
transcription rate of the gene is, at least in part, responsible for
this effect, as demonstrated in nuclear run-on experiments (3).
Posttranscriptional regulation of collagen a1(I) mRNA has
been studied almost exclusively in fibroblasts (13, 14, 49, 50),
where its stability depended on culturing conditions. In NIH
3T3 fibroblasts, the mRNA has a half-life of between 4 h in
semiconfluent cultures and 9 h in confluent cultures (49). In rat
fibroblasts, the half-life of collagen a1(I) mRNA was measured
to be longer than 16 h (61). Treatment of fibroblasts with
transforming growth factor b caused an increase in collagen
a1(I) mRNA, which is due in part to stabilization of the
mRNA (49, 50).
Stability of most mRNAs is determined by sequences in their
39 untranslated regions (UTRs) (4, 11, 56). Collagen a1(I)
mRNA exists as two species, a 4.7-kb mRNA and a 5.7-kb
mRNA, depending which polyadenylation site is used (43). In
fibroblasts, a 67-kDa protein binds to the 39 UTR present in
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both the 4.7- and 5.7-kb collagen a1(I) mRNA species (34, 35).
However, its binding site has not been precisely mapped. The
binding activity of this protein decreases upon treatment of
cells with dexamethasone, which also decreases collagen a1(I)
mRNA levels, suggesting a stabilizing role of this protein (34).
Recently the same authors have suggested a role of regions
other than 39 UTR in controlling the turnover of collagen
a1(I) mRNA, based on experiments with hybrid mRNA com-
posed of the 59 human growth hormone RNA and 39 collagen
a1(I) RNA (33). There are no studies on the posttranscrip-
tional regulation of the collagen a1(I) gene in HSCs.
In this study, we have measured the steady-state level, the
rate of transcription, and the half-life of collagen a1(I) mRNA
in quiescent and activated HSCs. The results suggest predom-
inantly posttranscriptional upregulation of collagen a1(I)
mRNA in the activation process of HSCs. An RNA binding
activity targeted to the C-rich region in the 39 UTR of this
mRNA has been found. This binding activity is present in
cytoplasmic extracts of activated but not quiescent HSCs. Mu-
tation of the binding site decreases accumulation of mRNA
derived from a collagen minigene in transient transfection ex-
periments. Finally, we show that this binding activity shares at
least one subunit, aCP, with the complex which binds to and
stabilizes the human a-globin mRNA (64, 67).
MATERIALS AND METHODS
Plasmid constructs. Collagen minigenes contain 220 nucleotides (nt) of the
promoter of the mouse collagen a1(I) gene followed by the first six exons ligated
to the last four exons within the intronic sequences, truncated at the HindIII site
(277 nt downstream of the stop codon) and thus containing only the first poly-
adenylation signal.
For in vitro transcription to generate the RNA probes used in gel mobility shift
experiments, the EcoRI-HindIII fragment of the mouse collagen a1(I) gene from
nt 239 to 1277 (11 is the first nucleotide after the stop codon) was subcloned
into corresponding sites of the pGEM3zf1 vector (Promega). To generate a
shorter probe, the mouse collagen a1(I) gene from nt 123 to 155 was synthe-
sized as a double-stranded oligonucleotide and cloned into EcoRI-HindIII sites
of pGEM3zf1. The a-globin template contains nt 129 to 170 from the 39 UTR
of human a-globin gene (64). a-Globin and collagen RNA probes were tran-
scribed from these templates after linearization with an appropriate restriction
enzyme. Site-directed mutagenesis was performed by the method of Kunkel (31).
Riboprobes used for RNase protection assays were derived from the 375-nt
PstI-AvaI fragment from rat collagen a1(I) cDNA (clone py1R1; a gift from
David Rowe), cloned into HincII-PstI sites of the pGEM 3zf1 vector and from
the pTRI-GAPDH-rat antisense control template (Ambion). To generate an
RNA probe to detect expression of the collagen minigenes, exons 5 to 9 of mouse
collagen a1(I) cDNA were cloned into PstI-HindIII sites of pGEM4, and a
348-nt antisense RNA probe was transcribed after linearization with NheI. Sin-
gle-stranded DNAs (ssDNAs) used for hybridization in nuclear run-on experi-
ments were made by using helper phage R408 (Promega) after cloning of the rat
collagen cDNA PstI-AvaI fragment into the pGEM 3zf2 vector and the rat
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA 340-nt EcoRI-
HindIII fragment into plasmids pGEM 3zf1 and pGEM 3zf2, respectively.
RNA isolation and analysis. Total cellular RNAs were isolated by the method
of Chomczynski and Sacchi (9). RNase protection analysis was performed ac-
cording to a published procedure (8). Collagen a1(I) and GAPDH-specific ribo-
probes were hybridized with the same RNA sample to account for recovery of
the RNA. Reverse transcription-PCR analysis was done with 200 ng of total
RNA and a GeneAmp rTth DNA polymerase kit (Perkin-Elmer). For collagen
a1(I) mRNA, the primers were TTCCCTGGACCTAAGGGTACT and
TTGAGCTCCAGCTTCGCC, derived from two different exons within the re-
gion of the gene encoding the triple-helical domain of the protein (positions 1711
and 1824 relative to the start codon in cDNA). These primers give an amplifi-
cation product of 113 nt from spliced mRNA. For GAPDH mRNA, the primers
were TGGCCAAGGTCATCCATGAC and GAGTGGCAGTGATGGCA
TGG, which give an amplification product of 75 nt. Both sets of primers were
used together in a single amplification reaction. All gels were quantified by
phosphorimaging.
Isolation and culture of HSCs. HSCs were isolated by perfusion of the livers
of adult Sprague-Dawley male rats with collagenase and pronase. The resultant
cell suspension was washed and centrifuged over an arabinogalactan gradient as
described by Friedman et al. (16). HSCs were collected from the 4.5% arabi-
nogalactan interphase and purity estimated by autofluorescence of the cells by
UV microscopy. More than 90% of cells showed the characteristic autofluores-
cence. These cells were immediately used as quiescent HSCs in all experiments.
Cells from the 12% stractan interphase were seeded onto uncoated plastic tissue
culture dishes and cultured in Dulbecco’s modified medium supplemented with
10% fetal calf serum in a 5% CO2-humidified atmosphere. After 7 days of
culture, the cells were trypsinized and grown for additional 7 days, after which
they were harvested and used as activated HSCs.
NIH 3T3 fibroblasts were cultured and transfected according to standard
procedures (7). For estimation of mRNA half-lives, HSCs were incubated with
25 mg of actinomycin D per ml or 67 mM 5,6-dichlorobenzimidazole riboside
(DRB), and cells were harvested at indicated time points.
Preparation of cell extracts, mobility shift experiments, and UV cross-linking.
Quiescent or activated HSCs were resuspended in lysis buffer containing 10 mM
Tris-Cl (pH 7.4), 10 mM MgCl2, 3 mM NaCl, and 0.4% Nonidet P-40 (NP-40).
After incubation for 10 min on ice, the cells were centrifuged in an Eppendorf
tube for 10 min at 14,000 rpm, and the supernatant was collected as cytoplasmic
extract. The protein concentration was measured by the Bradford assay (Bio-
Rad), using bovine serum albumin (BSA) as a standard. Extracts were kept at
280°C. Uniformly labeled RNA probes were prepared by standard in vitro
transcription protocols using [32P]UTP (3,000 Ci/mmol; ICN) after linearization
of plasmids with appropriate restriction enzymes. For mobility shift experiments,
25 mg of extracts was incubated with 40,000 cpm of radiolabeled RNA probes in
15 mM KCl–1 mM dithiothreitol (DTT)–12 mM HEPES (pH 7.8)–0.24 mM
EDTA–5 mM MgCl2–0.4% NP-40–200 ng of yeast tRNA per ml in a total volume
of 25 ml for 30 min at 30°C. Additionally, 10 mg of yeast tRNA was added to
suppress nonspecific binding. Competitor RNAs were added in some experi-
ments as indicated. These RNAs were made by in vitro transcription, and their
integrity was assessed by agarose gel electrophoresis. After incubation, 145 U of
RNase T1 (Gibco) was added, and incubation continued for 30 min at 30°C.
Finally, 3 ml of heparin (50 mg/ml) was added, and after 10 min of incubation on
ice, samples were loaded on a 6% nondenaturing acrylamide gel (acrylamide-
to-bisacrylamide ratio, 60:1). The gels were run in 0.33 Tris-borate-EDTA buffer
at ambient temperature. For photoaffinity cross-linking experiments, after addi-
tion of heparin, the samples were irradiated with 254-nm UV light from a
distance of 5 cm for 20 min, using a UVGL-2 lamp (UVP, Inc., San Gabriel,
Calif.); 250 U of Benzon nuclease (Sigma) was then added, and RNA was
digested for 30 min at 37°C. RNA-protein complexes were resolved by sodium
dodecyl sulfate (SDS)–10% polyacrylamide gel electrophoresis. To study the
effect of antibodies on RNA-protein binding, 10 ml of ascites fluid containing
anti-aCP monoclonal antibody 6B12.A3 was added to the binding reaction, while
10 ml of anti-human smooth muscle actin antibody (DAKO) was added to the
control reaction. The total mouse immunoglobulin G (IgG) fraction (2 mg/10 ml)
was supplemented with BSA to 5% (as total proteins in ascites fluid) and added
as an additional control reaction.
Nuclear run-on experiments. Nuclei were prepared from 1.5 3 107 quiescent
or activated HSCs by incubating cells for 10 min on ice in 10 mM Tris-Cl (pH
7.4)–3 mM CaCl2–2 mM MgCl2–1 mM DTT–0.1 mM phenylmethylsulfonyl
fluoride–50 U of RNasin (Promega) per ml–0.4% NP-40, followed by Dounce
homogenization. Cell lysis was checked microscopically, and samples were mixed
with 4 volumes of 0.1 M Tris-Cl (pH 7.4)–10 mM NaCl–3 mM MgCl2 and
centrifuged for 10 min at 500 3 g. The nuclear pellet was resuspended in 200 ml
of 50 mM Tris-Cl (pH 8.3)–5 mM MgCl2–0.1 mM EDTA–40% glycerol–1 mM
DTT–0.1 mM phenylmethylsulfonyl fluoride–50 U of RNasin per ml, flash frozen
in liquid N2, and stored at 280°C. Nuclear run-on experiments were done by
mixing 200 ml of nuclei with 200 ml of solution containing 140 mM KCl, 12.5 mM
MgCl2, 6.25 mM DTT, 0.25 mM EDTA, 1 mM each ATP, CTP, and GTP, and
0.5 mCi of [32P]UTP (3,000 Ci/mmol). After a 30-min incubation at 30°C, nuclei
were treated with 40 U of RNase-free DNase I (Boehringer) for 15 min at 37°C;
400 ml of a 2% SDS–20 mM Tris-Cl (pH 7.5)–10 mM EDTA solution and 8 ml
of proteinase K (20 mg/ml) were added, and incubation was continued for an
additional 30 min. Samples were then extracted with phenol-chloroform, ethanol
precipitated with 0.5 volume of 7.5 M ammonium acetate and 2.5 volume of
ethanol, redissolved in 200 ml of 10 mM Tris-Cl (pH 7.4)–10 mM NaCl–5 mM
MgCl2–1 mM CaCl2, and digested with 200 U of RNase-free DNase I for 60 min
at 37°C. RNA was again extracted with phenol-chloroform and ethanol precip-
itated as described above. Finally, samples were dissolved in hybridization buffer
[50 mM piperazine-N,N9-bis(2-ethanesulfonic acid) (PIPES; pH 6.5), 100 mM
NaCl, 50 mM sodium phosphate (pH 7), 1 mM EDTA, 5% SDS]. Then 2.5 mg
of ssDNA containing reverse complement sequences of the rat collagen a1(I)
gene or the GAPDH gene (minus strand) and 2.5 mg of ssDNA containing the
respective coding sequences (plus strand) were blotted onto a Hybond-N mem-
brane (Amersham). In one control experiment, we had blotted 5 mg of double-
stranded plasmid DNA, either without insert or with a collagen a1(I) or GAPDH
insert (see above). In one experiment, quiescent HSCs produced 5.6 3 106
cpm/1.5 3 107 nuclei, while activated HSCs produced 6.1 3 106 cpm/1.5 3 107
nuclei. Membranes were prehybridized for 2 h at 65°C, after which 5 3 106 cpm
of nuclear run-on transcripts from quiescent and activated HSCs was hybridized
in 200 ml of hybridization buffer for 3 days. Membranes were washed once for 15
min at room temperature (RT) in 5% SDS–13 SSC (0.15 M NaCl plus 0.015 M
sodium citrate) and twice for 30 min at 65°C in 0.1% SDS–0.13 SSC. To reduce
background, membranes were rinsed once in 100 mM sodium phosphate (pH
7.2) and digested with 10 mg of RNase A per ml and 350 U of RNase T1 (Gibco)
for 30 min at 37°C. Following rinsing in 100 mM sodium phosphate, membranes
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were subjected to autoradiography for 3 days with an intensifying screen and
quantitated with a phosphorimager.
Immunohistochemical analysis. Culture-activated HSCs were grown on cov-
erglasses in six-well dishes. Cells were fixed in 4% formalin (in phosphate-
buffered saline [PBS]) for 15 min at RT and washed twice with PBS before
permeabilization with 0.2% Triton X-100 (in PBS) for 10 min at RT. After two
washes with PBS, blocking was performed with 2% goat serum diluted in PBS for
30 min at RT. The slides were incubated for 1 h at RT with either anti-aCP
monoclonal antibody 6B12.A3 diluted 1:10 in PBS or anti-smooth muscle actin
monoclonal antibody 1A4 (DAKO). Subsequent incubations with biotinylated
secondary antibody and avidin-biotinylated enzyme complex was performed with
a Vectastain ABC kit (Vector Laboratories, Inc., Burlingame, Calif.) as in-
structed by the manufacturer. Color was developed by incubating the slides for
5 to 10 min with diaminobezidine, using Fast-DAB tabs (Sigma Chemical Co., St.
Louis, Mo.).
Western and Northwestern blots. Cytosolic protein extracts (S100) were pre-
pared as previously described (64). Proteins were separated on an SDS–12.5%
polyacrylamide gel and electroblotted onto a nitrocellulose membrane in buffer
containing 25 mM Tris, 192 mM glycine, and 15% methanol. For Western
analysis, filter blocking and antibody binding were performed as described pre-
viously (23). The polyclonal anti-aCP antibody was raised in chickens (Cocalico
Biologicals, Inc.) against bacterially expressed and gel purified aCP-1 (to be
detailed elsewhere). The antibody was purified from chicken yolks as described
previously (40). Primary antibody was used at 1:10,000 dilution followed by
secondary antibody (horseradish peroxidase-conjugated goat anti-chicken IgG;
Accurate Antibodies) used at 1:7,000 dilution. The antibody complexes were
detected by using the Amersham ECL system. For Northwestern analysis, the
proteins were renatured in situ by incubating the membrane in renaturing buffer
(10 mM Tris-Cl [pH 7.4], 50 mM NaCl, 1 mM EDTA, 13 Denhardt solution, 1
mM DTT) for 2 h at RT. Following renaturation, the membrane was incubated
with 32P-labeled poly(C) probe (20,000 cpm/ml) in hybridization buffer (10 mM
Tris-Cl [pH 7.4], 50 mM NaCl, 1 mM EDTA, 13 Denhardt solution, 20 mg of
tRNA per ml, 5 mg of heparin per ml) for 2 h at RT. The membrane was then
washed three times (10 min each) in 10 mM Tris-Cl (pH 7.4)–50 mM NaCl–1
mM EDTA–13 Denhardt solution at RT and exposed to X-ray film with an
intensifying screen.
RESULTS
Upregulation of collagen a1(I) mRNA in rat HSCs is me-
diated by a posttranscriptional mechanism. The steady-state
level of collagen a1(I) mRNA was measured by an RNase
protection assay in freshly isolated quiescent rat HSCs or ac-
tivated HSCs cultured on plastic for 14 days. Collagen- and
GAPDH gene-specific riboprobes were simultaneously hybrid-
ized, the latter serving as an internal control for recovery of the
RNA. We assumed that there is no change in GAPDH mRNA
levels between quiescent and activated HSCs, and we normal-
ized expression of collagen a1(I) mRNA to that of GAPDH
mRNA. In quiescent HSCs, a very low level of collagen a1(I)
mRNA is detected (Fig. 1A, lane 5) in this overexposed auto-
radiogram. The activated HSCs (lane 6) accumulated approx-
imately 70-fold more collagen a1(I) mRNA than did quiescent
HSCs. Similar results have been previously reported for qui-
escent and activated HSCs in vivo and in culture (36, 65).
To assess the contribution of increased transcription of the
collagen a1(I) gene in this dramatic upregulation, we per-
formed nuclear run-on experiments with nuclei from freshly
isolated HSCs and activated HSCs. Again we compared the
rate of transcription of the collagen a1(I) gene to that of the
GAPDH gene as a control. We hybridized nascent transcripts
to ssDNAs immobilized on a membrane to increase the sensi-
tivity of the assay and to distinguish between transcription from
the coding and noncoding strands. The minus-strand ssDNA
contains sequences complementary to the RNA transcribed
from the collagen or GAPDH gene, and thus a signal in this
slot indicates RNA polymerase II loading on the collagen (or
GAPDH) gene. The plus-strand ssDNA contains sequences
identical to those of the RNA originating from the collagen or
GAPDH gene and therefore detects transcription in the oppo-
site direction. We hybridized equal amounts (counts per
minute) of nascent transcripts of nuclei from quiescent and
activated HSCs. We found that activated HSCs have a tran-
scriptional rate of the collagen a1(I) gene that is twofold-
higher than that of quiescent HSCs (Fig. 1B). Since the rate of
incorporation of radioactivity into nuclei was 15% higher in
activated than quiescent HSCs, the activated HSCs had a 2.3-
fold-higher transcriptional rate/nucleus of the collagen a1(I)
gene. The signal from plus-strand ssDNA is much weaker,
suggesting no significant transcription on the noncoding DNA
strand or hybridization to plasmid sequences. GAPDH gene is
also transcribed at a slightly higher rate in activated HSCs than
in quiescent HSCs. However, the GAPDH gene in activated
HSCs also has a signal from plus-strand ssDNA. This probably
represents transcription from the noncoding DNA strand of
this gene, but the significance of this observation is unknown.
We have repeated the nuclear run-on experiment and hybrid-
ized the nascent transcripts to double-stranded DNA se-
quences with the same result. As a negative control, we in-
cluded an empty plasmid which showed no hybridization (data
not shown).
Since the increased transcription rate of the collagen a1(I)
gene accounted for only a small increase in the steady-state
levels of its mRNA, we decided to investigate the stability of
the collagen a1(I) mRNA in quiescent and activated HSCs.
We first used actinomycin D to block transcription because
previous measurements of the collagen mRNA half-life by
FIG. 1. Collagen a1(I) mRNA expression in HSCs. (A) RNase protection
assay with collagen a1(I) (lane 1) and GAPDH (lane 2) gene-specific riboprobes
and total RNA extracted from quiescent (Q; lane 5) and activated (A; lane 6)
HSCs. Protected bands are indicated by arrows. Lane 3, pBR322/MspI size
marker; lane 4, tRNA control. (B) Nuclear run-on transcription in nuclei isolated
from quiescent (Q) HSCs and (A) activated HSCs. Equal amounts (counts per
minute) of nascent RNA were hybridized to ssDNA containing collagen a1(I) or
GAPDH coding (1) or complementary (2) sequence. (C) mRNA stability assays
using either actinomycin D (Act. D; lanes 1 to 7) or DRB (lanes 8 to 14). Reverse
transcription-PCR analysis of 200 ng of total RNA extracted from quiescent
(lanes 2 and 3) or activated (lanes 5 to 7) HSCs incubated with actinomycin D (25
mg/ml) for the indicated time periods. In lanes 2 to 7, the RNA was simulta-
neously analyzed with primers specific for collagen a1(I) and GAPDH mRNAs.
Products of 76 nt (GAPDH) and 113 nt (collagen [COLL]) were resolved on a
6% denaturing gel and are indicated by arrows. Lanes 1 and 4 contain a pBR322/
MspI size marker. Lanes 8 to 14 represent an RNase protection assay with RNA
isolated from quiescent (lanes 9 to 11) or activated (lanes 12 to 14) HSCs treated
with 67 mM DRB for the indicated time periods. Arrows indicate protected
bands. Lane 8 represents a control reaction with tRNA.
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pulse-chase methods and using actinomycin D produced sim-
ilar results in fibroblasts (21). Preliminary experiments dem-
onstrated that collagen a1(I) mRNA decays very slowly in
activated HSCs; therefore, these cells were incubated for up to
24 h with actinomycin D. During this time period, the cells
remained morphologically unchanged. Quiescent HSCs were
incubated with actinomycin D for only 3 h. For more sensitive
detection of already very low collagen a1(I) mRNA levels in
quiescent HSCs, we used a reverse transcription-PCR analysis.
Two sets of primers, one specific for collagen a1(I) mRNA and
the other specific for GAPDH mRNA, were used for this assay.
Collagen primers were derived from two exons to discriminate
a signal originating from potentially contaminating DNA. Am-
plification with these primers was not affected by the presence
of GAPDH primers (data not shown). Both sets of primers
were used together in an amplification reaction which was
limited to 20 cycles. In quiescent HSCs, the collagen a1(I)
mRNA level had decreased to 25% of the starting level at 3 h
after the inhibition of transcription (Fig. 1C, lane 3). In acti-
vated HSCs, more than 50% of the collagen a1(I) mRNA still
remained after 24 h of actinomycin D treatment (Fig. 1C;
compare lanes 5 and 7), suggesting a markedly increased sta-
bility compared to quiescent HSCs. During this time, GAPDH
mRNA showed only about 30% decay, indicating that it may be
slightly more stable than collagen a1(I) mRNA. To show that
actinomycin D had indeed blocked transcription in activated
HSCs, we reprobed the same RNA samples for the presence of
histone H3 mRNA, which is known to have a half-life of about
3 h in slowly dividing cells (1). As expected, this mRNA could
not be detected in cells incubated with actinomycin D for 12 or
24 h (data not shown). We quantitated relative abundances of
collagen and GAPDH mRNAs in the time zero samples and
found that there was 60-fold more collagen a1(I) mRNA in
activated than in quiescent HSCs. This result is in a good
agreement with data obtained by an RNase protection assay
(Fig. 1A and C) and confirms the validity of our reverse tran-
scription-PCR assay. From this experiment, we estimated by
interpolation (56) that collagen a1(I) mRNA has half-lives of
1.5 h in quiescent HSCs and 24 h in activated HSCs.
We also measured the half-life of collagen a1(I) mRNA in
HSCs by using the inhibitor of transcription DRB and quan-
titated expression by an RNase protection assay (Fig. 1C, lanes
9 to 14). In quiescent HSCs, collagen a1(I) mRNA was unde-
tectable both 3 and 6 h after addition of DRB (compare lanes
9, 10, and 11). In activated HSCs, there was only a 50% de-
crease in the level of this mRNA 24 h after addition of the
inhibitor. Thus, experiments with two inhibitors, actinomycin
D and DRB, and two assays for mRNA levels consistently
demonstrate a longer half-life of collagen a1(I) mRNA in
activated HSCs than in quiescent HSCs.
RNA binding proteins interact with the collagen a1(I) 3*
UTR and are differentially expressed in HSCs. The stability of
most mRNAs is mediated by sequences in their 39 UTRs and
controlled by proteins binding to them (4, 11, 56). Therefore,
we decided to examine the 39 UTR of collagen a1(I) mRNA
for protein binding activity. We derived a 316-nt RNA probe
spanning the whole 39 UTR of the mouse 4.7-kb mRNA as well
as 39 nt of the coding region (Fig. 2A) and incubated this
probe with cytoplasmic extracts made from quiescent and ac-
tivated HSCs. We detected an RNA-protein complex in ex-
tracts from activated but not quiescent HSCs (Fig. 2A, lanes 2
and 3). This RNA has a C-rich region located 22 nt 39 to the
stop codon (Fig. 2A, W). Substitution of this C-rich sequence
with 25 nt of an unrelated sequence (M1 in Fig. 2A) greatly
FIG. 2. RNA binding proteins interact with the 39 UTR of collagen a1(I) mRNA. (A) Gel mobility shift experiment using a 316-nt RNA probe spanning the whole
39 UTR. The sequences of the wild-type (W) and mutant (M1) RNA probes are shown at the top. In lanes 1 to 3 25 mg of BSA (lane 1) or cytoplasmic extract from
activated (A; lane 2) or quiescent (Q; lane 3) HSCs was incubated with 40,000 cpm of the W probe. After digestion with RNase T1 and addition of heparin, complexes
were resolved on a 6% native acrylamide gel. Positions of the RNA-protein complex (full arrow) and free RNA (open arrows) are indicated. In lanes 4 to 7, the W
probe (lanes 4 and 6) and M1 probe (lanes 5 and 7) were incubated with BSA (lanes 4 and 5) or activated HSC cytoplasmic extract (lanes 6 and 7) and analyzed by
gel mobility shift. (B) Gel mobility shift with the 33-nt C-rich RNA probe. The sequence of the probe is shown at the top. This probe was incubated with 25 mg of BSA
(lanes 1 and 6), 25 mg of quiescent HSC cytoplasmic extract (lane 2), or 25 mg of activated HSC cytoplasmic extract (lanes 3 to 5 and 7 to 11). A 100-fold molar excess
of specific competitor (collagen [COLL]; lane 4) or nonspecific (NS) competitor (lane 5) was added. Poly(C) and poly(U) had an average size of 200 nt and were added
in 100-fold (lanes 8 and 10) and 200-fold (lanes 9 and 11) molar excess. (C) UV cross-linking of proteins to the 39 UTR of the collagen a1(I) mRNA. The sequence
of the W probe is shown in panel A. The mutant probe (M2) has substitutions in a part of the C-rich sequence, as shown at the top. Sixty micrograms of cytoplasmic
extract from activated HSCs (A; lanes 1 to 3) or from NIH 3T3 fibroblasts (FIB; lanes 4 and 5) was used in the binding reaction. After UV irradiation and extensive
RNase digestion, samples were resolved on an SDS–10% polyacrylamide gel (lanes 2 to 5). Lane 1 is the sample without UV irradiation. The size markers (positions
indicated in kilobases) are low-molecular-weight prestained protein size markers from Amersham. The arrows indicate the positions of RNA-protein complexes.
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diminishes protein binding to the entire 39 UTR (compare
lanes 6 and 7), suggesting the importance of this sequence for
protein interaction. To show that this sequence is not only
necessary but also sufficient for the interaction, we derived a
short RNA probe spanning only the C-rich sequence (Fig. 2B).
Again, in quiescent HSCs no protein binding could be dem-
onstrated (lane 2), while an RNA-protein complex was effi-
ciently formed in extracts from activated HSCs (lane 3). This
binding was competed with an excess of specific competitor
(lane 4); an excess of nonspecific competitor has almost no
effect (lane 5). The binding to the collagen a1(I) mRNA 39
UTR is also effectively competed with excess poly(C) (lanes 8
and 9) but not with excess poly(U) (lanes 10 and 11).
To provide insight into proteins that are present in the
complex which binds collagen a1(I) mRNA, we performed a
photoaffinity cross-linking experiment. Using the 316-nt probe
(identical to that shown in Fig. 2A) and extracts from activated
HSCs (Fig. 2C, lanes 1 to 3) or NIH 3T3 fibroblasts (lanes 4
and 5), two proteins were cross-linked; one protein-RNA com-
plex has a size of about 45 kDa, and the other has a size of
about 40 kDa. No cross-linked proteins were detected in ex-
tracts from quiescent HSCs. When we used the short probe
(identical to that shown in Fig. 2B) in UV cross-linking exper-
iments, the 45-kDa complex, but not the 40-kDa complex, was
formed (data not shown). Since U is a photosensitive nucleo-
tide in RNA, proteins are almost always cross-linked to RNA
at U residues (22). We reasoned that the C-rich sequence is
required for binding of the complex and that the U’s found
within this sequence are necessary for formation of the cross-
link. Therefore, we mutated the 39 portion of the C-rich region
identified in the previous experiment as the protein binding
site and analyzed cross-linking to this mutant (M2 [Fig. 2C]).
This substitution abolished formation of the 45-kDa complex,
while the 40-kDa complex could still be demonstrated (lanes 3
and 5), suggesting that this protein cross-links to another U(s)
on this 316-nt RNA.
From the foregoing experiments, we concluded that there is
an RNA binding activity that is targeted to the C-rich region in
the 39 UTR of collagen a1(I) mRNA. This activity is absent
from cytoplasmic extracts of quiescent HSCs, where the
mRNA has a short half-life, and is present in extracts from
activated HSCs and fibroblasts, where its half-life is prolonged.
Therefore, it may be involved in stabilization of collagen a1(I)
mRNA in HSCs. A protein of about 45 kDa seems to be an
RNA binding subunit of this activity, as suggested by UV
cross-linking experiments.
Expression of collagen minigenes. To provide evidence for a
functional significance of this RNA-protein interaction, we
used a collagen a1(I) minigene that is suitable for experimen-
tal manipulations. Transcription of this gene is driven by 220 nt
of the promoter, followed by its first six exons ligated to its four
last exons. We truncated the minigene to contain only the first
polyadenylation site (Fig. 3A). In the 39 UTR of this minigene
(W), we created the same substitution (M2) which abolished
formation of the 45-kDa RNA-protein complex (Fig. 2). W and
M2 minigenes with a luciferase reporter gene plasmid (to con-
trol for transfection efficiency) were transiently transfected
into NIH 3T3 fibroblasts, and accumulation of the mRNA
derived from the minigenes and the endogenous collagen a1(I)
gene was analyzed by an RNase protection assay. Fibroblasts
were used because activated HSCs cannot be efficiently trans-
fected to allow for such analysis. Also, collagen a1(I) mRNA
has a long half-life in fibroblasts, which contain the binding
activity to the 39 UTR (Fig. 2). We quantitated the expression
of minigene mRNA and corrected for transfection efficiency by
analyzing luciferase activity. Figure 3B shows the result of
three independent transfections. RNA derived from the M2
minigene accumulated to 60% of the level of RNA transcribed
from W minigene. This result is consistent with the model that
binding of a protein of approximately 45-kDa to the 39 UTR of
collagen a1(I) mRNA increases the steady-state level of this
mRNA. Stable cell lines of NIH 3T3 cells expressing the mini-
genes produced similar results, with the half-life of the mRNA
from the M2 minigene being 35% that of the mRNA from the
W minigene (Fig. 3C).
aCP is a subunit of a complex that binds collagen a1(I)
mRNA 3* UTR. aCP is a ubiquitous 39-kDa protein (based on
FIG. 3. Expression of collagen a1(I) minigenes. (A) Schematic representa-
tion of collagen a1(I) minigenes. Exons are shown as boxes; promoter, introns,
and 39 UTR are represented by lines (not to scale). The point of ligation of the
59 portion to the 39 portion of the gene is indicated. The wild-type sequence of
the 45-kDa cross-link site (W) and the mutation introduced (M2) are shown. (B)
Quantitation of expression of W and M2 collagen a1(I) minigenes. Collagen
minigenes were cotransfected with the luciferase gene into NIH 3T3 fibroblasts,
and the mRNA level was analyzed by RNase protection assay. In three separate
experiments, expression of the minigenes was quantified relative to that of the
endogenous collagen a1(I) gene by phosphorimage scanning of the gels and
corrected for transfection efficiency by analyzing luciferase activity. Expression of
the W minigene was arbitrarily set at 100%. The error bar shows standard
deviation. (C) Comparison of the mRNA half-lives of W and M2 collagen a1(I)
minigenes. The W and M2 collagen a1(I) minigenes were stably transfected into
NIH 3T3 fibroblasts and the stable cell lines were incubated with actinomycin D
for 0 or 24 h in two separate experiments. Collagen a1(I) mRNA levels were
quantified by RNase protection assays and expressed as the ratio of the mRNA
level at 24 h to that at 0 h. This ratio for the W minigene was arbitrarily set at 1.0.
The error bar shows standard deviation.
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the predicted amino acid sequence) which has been cloned by
its ability to bind poly(C) nucleic acids (20). Our UV cross-
linking and RNA binding experiments (Fig. 2) identified a
protein of about 45 kDa that preferentially binds the C-rich
sequence in the 39 UTR of the collagen a1(I) mRNA. Taking
into account that cross-links always contain a small portion of
RNA, which can affect the apparent molecular weight of the
protein, we investigated whether our 45-kDa protein is in fact
aCP. First, we determined whether cytoplasmic extracts from
HSCs contain aCP by Western and Northwestern analyses.
S100 extracts from K562 cells served as a positive control in
these experiments. Figure 4A shows that antibodies against
aCP detected proteins of corresponding sizes in both quiescent
and activated HSCs extracts. The levels were similar or slightly
greater in quiescent HSCs.
aCP alone can bind poly(C) homopolymers but not degen-
erate C-rich sequences such as the a-globin sequence (29, 64).
Results of Northwestern analysis using an ssDNA poly(C) oli-
gonucleotide as a probe were similar to those of the aCP
Western blot analysis (Fig. 4AB), suggesting that aCP is
present in extracts of quiescent and activated HSCs. The
[32P]poly(dC) probe also reacts in the Northwestern analysis
with hnRNP-K, which is sometimes seen in cytoplasmic extract
preparations as a result of nuclear contamination. Therefore,
we performed immunostaining of activated HSCs to investi-
gate subcellular localization of aCP in HSCs. aCP appears
uniformly distributed in activated HSCs, being present in the
cytoplasm as well as in the nucleus (data not shown). To
establish whether aCP is actually present as a component of
binding activity to the collagen a1(I) 39 UTR, we performed a
binding experiment in which we added either an aCP-specific
antiserum or nonspecific antiserum to the extracts of activated
HSCs and compared their abilities to bind the collagen probe
by gel retardation analysis. The aCP-specific antibody (Fig. 4C,
lane 3) abolished formation of the RNA-protein complex
whereas nonspecific antibodies (lanes 4 and 5) had no effect,
suggesting that aCP is required for formation of this RNA
binding activity. Since activated but not quiescent HSCs can
bind to the collagen a1(I) 39 UTR, although they both contain
aCP, it seems that aCP is necessary but not sufficient to pro-
mote protein binding to the collagen a1(I) 39 UTR. Alterna-
tively, aCP may be modified in activated HSCs.
a-Globin and collagen a1(I) 3* UTR binding activities. Col-
lagen a1(I) mRNA has a half-life of 24 h in activated HSCs
(Fig. 1), and a 45-kDa protein (as estimated by UV cross-
linking [Fig. 2]), probably as a part of a multiprotein complex,
interacts with the C-rich sequence in its 39 UTR. This interac-
tion may be responsible for stabilization of the mRNA. Human
a-globin mRNA has half-life of days in reticulocytes (67), and
the 39 UTR of this mRNA has a C-rich sequence, which is not
identical to that of collagen a1(I) mRNA (64). A ubiquitous
poly(C) binding protein of 39 kDa was identified as a compo-
nent of this binding activity and shown to be identical to aCP
(29). We investigated the relationship between the RNA bind-
ing proteins that bind to these C-rich sequences in the collagen
a1(I) and a-globin mRNAs 39 UTRs. We performed RNA
binding and competition experiments with collagen a1(I) and
a-globin sequences (Fig. 5). In agreement with our previous
data (Fig. 2), there is no binding activity to the collagen a1(I)
C-rich sequence in quiescent HSCs (lane 2), while it is readily
observable in activated HSCs (lane 3). To our surprise, in
quiescent HSCs we could detect a complex formed on the
a-globin C-rich sequence (lane 5). In activated HSCs, there is
a binding activity to the a-globin sequence as well, although it
has higher electrophoretic mobility and is resolved as two
bands (lane 6). It also has a different electrophoretic mobility
than the complex formed on the collagen probe (compare
lanes 3 and 6). These data suggest that the complexes binding
collagen a1(I) and a-globin C-rich sequences are composed of
different subunits. Although quiescent HSCs contain aCP, the
accessory component(s) necessary for binding the collagen
a1(I) mRNA is lacking, but the accessory components neces-
sary for binding to the a-globin mRNA are present.
Next we performed cross-competition studies where we
competed binding to the collagen a1(I) sequence with the
a-globin sequence and vice versa in cytoplasmic extracts from
FIG. 4. aCP is a subunit of a protein complex binding the collagen a1(I)
mRNA 39 UTR. (A) Western analysis done with 40 mg of cytoplasmic extracts
from quiescent (Q) and activated (A) HSCs and S100 extract from K562 human
erythroleukemia cells. The blot was probed with a polyclonal antibody directed
against aCP. (B) Northwestern blot with the same extracts, probed with 20,000
cpm of 59-end-labeled poly(C). Positions of the aCP and hnRNP-K proteins are
indicated. (C) Inhibition of collagen a1(I) mRNA 39 UTR binding activity with
the anti-aCP monoclonal antibody (Ab). RNA binding was done by mixing 25 mg
of extracts from activated HSCs with 10 ml of 5% BSA (lane 2), 10 ml of ascites
fluid containing anti-aCP antibody 6B12.A3 (lane 3), 10 ml of ascites fluid
containing anti-smooth muscle actin (SMA) antibody (lane 4), or 2 mg of mouse
IgG in 10 ml of 5% BSA (lane 5). Lane 1 is a control reaction without extract.
After incubation with the 33-nt probe (Fig. 2B) and RNase T1 digestion, the
complexes were resolved on a 6% native acrylamide gel. Positions of free RNA
(open arrows) and RNA-protein complexes (full arrow) are indicated.
FIG. 5. Cross-competition between collagen a1(I) and a-globin RNA pro-
tein binding sequences. A gel mobility experiment was done as for Fig. 2. The
RNA probes were the collagen a1(I) (COLL) sequence shown in Fig. 2B and
human a-globin (aGL) nt 129 to 170 from the 39 UTR. The same unlabeled
RNAs were used as competitors as indicated. The nonspecific competitor (NS)
was a 434-nt RNA derived from the antisense strand of the rat GAPDH cDNA.
The competitors were added in 100-fold molar excess. The positions of free RNA
(open arrows) and RNA-protein complexes (full arrows) are indicated.
5206 STEFANOVIC ET AL. MOL. CELL. BIOL.
quiescent and activated HSCs (Fig. 5, lanes 7 to 15). In quies-
cent HSCs, interaction with the a-globin probe was not com-
peted with a 100-fold molar excess of the collagen a1(I) se-
quence (lane 8) or with excess nonspecific sequence (lane 9). It
was effectively competed with the same molar excess of specific
competitor (lane 7). Therefore, the collagen sequence neither
binds proteins nor competes for binding to the a-globin se-
quence in extracts from quiescent HSCs. In activated HSCs,
the collagen a1(I) sequence partially inhibited binding to the
globin probe (compare lanes 11 and 12, which contains the
nonspecific competitor), although not as well as the a-globin
sequence itself (lane 10). Thus, in activated HSCs, there is
some degree of cross-competition between a-globin- and col-
lagen C-rich sequences, implying that they share at least one
component required for binding. Since activated HSCs contain
all accessory components to promote formation of an aCP-
containing complex on the collagen sequence, it is likely that
sequestration of aCP in these complexes by an excess of the
collagen sequence inhibited binding to the a-globin probe. The
opposite also seems to be true in that the a-globin sequence
efficiently competes binding to the collagen probe (lane 14),
again somewhat better than the collagen sequence itself (lane
13). Presence of a nonspecific RNA sequence has no influence
on binding (lane 15).
DISCUSSION
We have investigated mechanisms controlling the increase
of collagen a1(I) mRNA during activation of HSCs and have
demonstrated three main observations: (i) the regulation of
collagen a1(I) mRNA is predominantly posttranscriptional,
(ii) this regulation is correlated with a differentially expressed
RNA binding activity, and (iii) this binding activity contains as
a subunit aCP, which is also involved in stabilization of a-
globin mRNA (67). There is 60- to 70-fold increase in collagen
a1(I) mRNA steady-state level in activated HSCs compared to
quiescent HSCs (Fig. 1A). Similar increases were observed by
other investigators for activated HSCs in culture (25, 37, 65)
and in vivo (36, 66). In our study, activated HSCs transcribe the
collagen a1(I) gene at a rate twofold higher than that for
quiescent HSCs (Fig. 1B), which is insufficient to account for a
60- to 70-fold increase in the mRNA accumulation.
Injection of CCl4 into experimental animals results in ap-
proximately a 30-fold increase in collagen a1(I) mRNA in total
liver RNAs (unpublished observation and reference 8). There
is about a twofold increase in collagen a1(I) gene transcription
in total liver nuclei from CCl4-treated rats compared to normal
liver nuclei (47, 48). Taking into account that HSCs are the
major liver cells capable of upregulating collagen a1(I) mRNA
following a fibrogenic stimulus (36), these results are in excel-
lent agreement with what we have found in this study for
culture-activated HSCs. On the other hand, expression of a
reporter gene driven by the collagen a1(I) minimal promoter
was increased about 40-fold in activated compared to quies-
cent HSCs (25). The different results from the reporter gene
assay and the nuclear run-on assays might reflect aberrant
expression of the multicopy reporter gene, which was missing
collagen a1(I) gene regulatory elements (references 3 and 54
and unpublished observations). Alternatively, the nuclear
run-on assays could overestimate synthesis of the full-length
mRNA in quiescent HSCs, such as could be produced by a
block of transcriptional elongation (30).
Measurement of the collagen a1(I) mRNA half-life in HSCs
has not been done previously. The data presented in Fig. 1C
suggest that an important posttranscriptional mechanism reg-
ulating collagen a1(I) mRNA involves stabilization of the
mRNA. We have estimated by interpolation (56) that the half-
lives of collagen a1(I) mRNA are 1.5 h in quiescent HSCs and
24 h in activated HSCs (Fig. 1C). Although we did not precisely
measure the half-life, this is a dramatic change in stability of
this mRNA. With only a moderately increased transcription
rate of the gene, this increase in stability is primarily respon-
sible for the observed increase in steady-state levels of collagen
a1(I) mRNA in HSCs. Experiments with fibroblasts have
shown that collagen a1(I) mRNA can be regulated at the level
of mRNA stability, and in these cells the stability can be mod-
ulated by culturing conditions and hormonal treatment (14, 15,
33, 48, 49). The half-life of collagen a1(I) mRNA in NIH 3T3
and human skin fibroblasts, cultured under conditions similar
to those used for HSCs in our study, was estimated to be 9 h
(21, 49), while it is more than 16 h in rat fibroblasts (reference
61 and unpublished results) and even longer in activated HSCs.
The synthetic pathway of the collagen a1(I) mRNA in HSCs
is unknown. Collagen a1(I) mRNA may be associated with
polysomes and translated throughout its functional life, so that
it would synthesize abundant protein even if relatively ineffi-
ciently translated. Alternatively, it may be sequestered within a
cytoplasmic compartment, with only a fraction targeted for
translation. The conserved stem-loop structure overlapping the
translation initiation codon in collagen a1(I) mRNA, also
found in a2(I) and a1(III) mRNAs (69), may be involved in
regulation of these processes. This stem-loop structure can
inhibit in vivo and in vitro translation of a chimeric mRNA
(unpublished observation).
Theoretically, in quiescent HSCs, collagen a1(I) mRNA
may be actively degraded, may be unstable by a default mech-
anism and stabilized during activation of HSCs, or may be
regulated by a combination of the two effects. In activated
HSCs, this mRNA undergoes a dramatic stabilization (Fig.
1C). Stability of most mRNAs is regulated by sequences in
their 39 UTRs and determined by proteins interacting with
these sequences (4, 11, 56). An RNA binding activity to the 39
UTR of collagen a1(I) mRNA has been previously identified
in fibroblasts, but its binding site was not mapped (34). Here
we show that in HSCs, an RNA binding activity is targeted to
the C-rich sequence located 23 nt 39 to the stop codon (Fig. 2)
and that its binding correlates with accumulation of collagen
a1(I) mRNA in HSCs. At the similar position in the 39 UTR of
the a-globin gene there is a sequence consisting of three C-rich
regions, which combines with cytosolic proteins to form a se-
quence-specific complex, the a complex. Mutations within
these C-rich regions block complex formation in vitro (64). The
a complex is composed of three protein subunits (29, 64). The
smallest component is aCP, which belongs to the KH domain
family of RNA binding proteins and by itself is capable of
binding poly(C) and poly(dC) single-stranded nucleic acids
(20, 39, 64). However, the aCP cannot bind the a-globin se-
quence on its own; this interaction appears to be dependent on
the presence of accessory proteins. Mutation of the stop codon
in the a-globin gene into a missense codon is a naturally oc-
curring mutation that is associated with low levels of a-globin
mRNA and severe anemia (thalassemia Constant Spring) (67).
It has been proposed that ribosomes translating into the 39
UTR of Constant Spring a-globin mRNA are capable of dis-
placing the a complex, causing destabilization of the a-globin
mRNA. In transient transfection experiments, mutation of the
binding site for the a complex diminished accumulation of
a-globin mRNA to 30% of the wild-type level (67).
We performed a similar type of experiment in which muta-
tion of the collagen a1(I) mRNA C-rich sequence decreased
accumulation of mRNA derived from collagen minigenes to
60% of the wild-type level (Fig. 3). We also stably transfected
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NIH 3T3 cells with W and M2 collagen minigenes and mea-
sured the half-lives of endogenous collagen a1(I) mRNA and
minigene RNA with actinomycin D. Full-size collagen a1(I)
mRNA had a half-life of about 6 h, in accordance with previ-
ously published results (49), while minigene mRNA had a
half-life of longer than 24 h. However, the M2 minigene
mRNA had a 35% lower half-life than the W minigene mRNA
(Fig. 3C). The less pronounced effect of the mutation on col-
lagen minigene mRNA may reflect one of several possible
underlying mechanisms. Collagen minigene mRNA does not
contain all of the sequences present in full-size a1(I) mRNA,
and some long-range interactions important for proper folding
of this molecule may be missing (18, 58). In fact, the minigene
mRNA is more stable than the endogenous mRNA and there-
fore might blunt the effect of the destabilizing mutation. In the
mutation tested, we substituted 12 nt and abolished cross-
linking to a 45-kDa protein; however, cross-linking to a 40-kDa
protein persisted (Fig. 2C). Even changing the entire C-rich
sequence does not completely abolish protein binding to the 39
UTR (Fig. 2A, lane 7). It is possible that this yet uncharacter-
ized interaction also contributes to the stability of collagen
a1(I) mRNA. Therefore, results with minigene mRNAs can-
not be quantitatively extrapolated to naturally occurring colla-
gen a1(I) mRNA. Furthermore, additional regions of the col-
lagen a1(I) mRNA, such as the 59 UTR or coding region, may
also contribute to its increased stability in activated HSCs.
Our findings, nevertheless, suggest that the RNA-protein
interaction at the C-rich sequence in the 39 UTR may be
required for high-level accumulation of collagen a1(I) mRNA.
We believe that it stabilizes this mRNA because it involves an
RNA binding activity that shares at least one subunit with the
a complex. Based on inhibition of binding by the anti-aCP
antibody (Fig. 4C), competition of binding by poly(C) (Fig.
2B), and UV cross-linking (Fig. 2C), this subunit seems to be
aCP.
The collagen a1(I) C-rich sequence is shorter and different
from that of the a-globin sequence. However, in activated
HSCs, the a-globin sequence efficiently competes for binding
to the collagen sequence and the collagen sequence competes,
although slightly less effectively, for binding to the a-globin
sequence (Fig. 5), again suggesting interaction with a common
factor(s). The difference in the effectiveness of competition
may reflect slightly higher affinity of protein binding to the
a-globin sequence. aCP is a ubiquitous protein and is found in
extracts from quiescent HSCs (Fig. 4). We tested many extracts
from quiescent HSCs but could not detect binding to the col-
lagen sequence, while binding to the a-globin sequence was
readily demonstrable. In the quiescent HSC extracts, the col-
lagen sequence could not compete for binding to the a-globin
sequence. Since aCP alone cannot bind to degenerate C-rich
sequences, accessory components required for binding to the
collagen sequence are lacking in these extracts but those nec-
essary for binding to the globin sequence are present. Thus,
accessory factors mediating binding of aCP to the collagen
a1(I) and a-globin 39 UTRs are clearly different. This conclu-
sion is also suggested by the different electrophoretic mobili-
ties of complexes formed on collagen and globin probes in
activated HSCs extracts (Fig. 5; compare lanes 3 and 6). It is
possible that aCP has the ability to form an array of hetero-
mers by association with various auxiliary factors. In HSCs,
these auxiliary factors are differentially expressed and probably
regulatory for collagen a1(I) mRNA accumulation. Alterna-
tively, it is possible that aCP is modified in activated HSCs
such that it binds the collagen 39 UTR without participation of
auxiliary factors. If this is true, then such a modification is
subtle since we have not seen a difference in electrophoretic
mobility of aCP in extracts of quiescent and activated HSCs
(Fig. 4).
It is almost certain that more long-lived mRNAs that are
stabilized by aCP-containing complexes will be discovered.
Identification and characterization of auxiliary factors involved
in formation of the complex that binds collagen a1(I) mRNA
39 UTR in HSCs is an important goal. This analysis will provide
insight into the critical regulatory mechanism of collagen a1(I)
gene expression in HSCs and may lead to development of
drugs for treatment of liver fibrosis.
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